Clinical Trial

Technetium Tc 99m Sulfur Colloid Injection for Tracing Sentinel Nodes in Breast Cancer

Completed Phase 3
View on ClinicalTrials.gov →
Summary
The aim of the study is a prospective multicentre phase-3 study that aims to evaluate the detection rate of sentinel lymph node in patients with breast cancer. To compare the detection rates of Technetium Tc 99m Sulfur Colloid Injection(99mTc-SC) and Mitoxantrone Hydrochloride Injection for Tracing(MHI) for lymphatic tracing in patients with breast cancer.
Trial Details
NCT Number NCT07764653
Lead Sponsor HTA Co., Ltd.
Collaborators: Peking University Cancer Hospital & Institute, Peking University People's Hospital, Beijing Shijitan Hospital, Capital Medical University, Beijing Tongren Hospital, Xuanwu Hospital, Beijing, Tongji Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Renmin Hospital of Wuhan University
Conditions Sentinel Nodes, Breast Cancer
Enrollment 213 participants
Start Date 2024-01-02
Primary Completion 2025-06-03 (estimated)
Study Completion 2025-06-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-14